Answers are grounded in this paper and cite their sources.
Risankizumab treatment demonstrated high rates of rapid and durable efficacy as measured by absolute PASI thresholds and improvements in patient HRQoL.
No takes yet. Share an insight, caveat, or question.
Gooderham et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: